LGVN: Alzheimer's Treatment Gets Positive News from FDA
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
221 Views
LGVN: Great Position for Pivotal Year
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
229 Views
LGVN: Great Position for Pivotal Year
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
200 Views
LGVN: Positive Test Results Highlight Quarterly Results
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
171 Views
LGVN: Financial Update Highlights Successes
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
243 Views